Starting in 2025, crypto exchanges will be required to send you and the IRS a Form 1099-DA, similar to how stock brokers send ...

Despite their longstanding precedent against chopping prize pools, the World Series of Poker added an ICM calculator to its ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT-0.41%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.11%decrease; red down pointing triangle in a deal valued at about ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...